reason report
model chang updat elacestr partnership outlook pt
bottom line follow discuss manag week
last week present svb leerink global healthcar
confer adjust amount time
elacestr mileston payment reflect later complet
sale program royalti rather mileston
weight form contract manag confirm
activ late-stag discuss sever compani final
elacestr partnership agreement given on-going natur
discuss radiu anticip provid investor statu updat
within next month compani indic royalty-bas
agreement remain core part current strategi particularli
collabor includ right partner reiter belief
compani remain well financ bring on-going phase
trial complet expect complet trial enrol
base observ pickup trial enrol rate result
remain track provid phase data updat next year base
commentari adjust mileston forecast
model mileston payment previous
follow adjust includ mileston
payment potenti collabor agreement
mileston payment disclosur phase result
subsequ mileston payment us approv
eu approv result chang price
target lower reiter outperform rate
base dcf
discount rate termin growth
net debt total capit
net debt total capit balanc sheet debt
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
ep exclud stock option expens amort intang
pleas refer page import disclosur price chart analyst certif
price target inc rate stock
outperform radiu biopharmaceut compani uniqu concentr focu drug
address unmet need women health compani revenu today deriv
second subcutan osteoanabol introduc us osteoporosi market tymlo
abaloparatid trajectori tymlo us osteoanabol market share appear predict
base prescript data proprietari medacorp physician survey expect
tymlo obtain share forecast market share provid
peak us sale support valuat radiu stock upsid investor
come potenti introduct tymlo patch test pivot phase
studi tymlo patch would elimin burden daili needl inject open
much broader prescrib patient base believ could tripl number patient
treat tymlo radiu also develop phase asset elacestr select estrogen
receptor degrad serd late-lin metastat breast cancer partnership discuss
asset on-going price target contain signific probability-of-success adjust
two clinic program increment valu potenti come tymlo patch
month price target base dcf methodolog cash flow
termin valu forecast sale subcutan tymlo risk-
adjust sale tymlo patch elacestr assum discount rate base
compani wacc assum convert debt convert stock includ
dilut share calcul price target base current stock level
addit factor cash balanc valuat
risk view outlook valuat radiu includ major chang price
reimburs coverag unit state sc tymlo compani main product
today forecast product also subject risk better-than-expect market
share gain gener forteo unexpect competit respons forteo manufactur
launch new superior drug class osteoporosi risk radiu
includ develop regulatori disappoint tymlo patch oncolog asset
elacestr two product fail compani valuat would reduc
approxim addit whether tymlo sale match estim on-going
clinic trial success dilut financ like requir product launch
order support futur commerci oper clinic develop
brand chemic name
type event
event trial detail
svb leerink llc research compani file
date known
specifi
up/down
svb leerink view
million
licens revenu mileston fund
svb leerink research compani file
million
licens revenu mileston fund
sale
 total revenu
sg total revenu
svb leerink research compani file
